Syndax Pharmaceuticals (STU:1T3) Other Long Term Assets : €0.21 Mil (As of Dec. 2024)

View and export this data going back to 2017. Start your Free Trial

What is Syndax Pharmaceuticals Other Long Term Assets?

Syndax Pharmaceuticals's other long-term assets for the quarter that ended in Dec. 2024 was €0.21 Mil.

Syndax Pharmaceuticals's quarterly other long-term assets declined from Jun. 2024 (€0.35 Mil) to Sep. 2024 (€0.20 Mil) but then increased from Sep. 2024 (€0.20 Mil) to Dec. 2024 (€0.21 Mil).

Syndax Pharmaceuticals's annual other long-term assets declined from Dec. 2022 (€0.87 Mil) to Dec. 2023 (€0.62 Mil) and declined from Dec. 2023 (€0.62 Mil) to Dec. 2024 (€0.21 Mil).

Syndax Pharmaceuticals Other Long Term Assets Historical Data

The historical data trend for Syndax Pharmaceuticals's Other Long Term Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Syndax Pharmaceuticals Other Long Term Assets Chart

Syndax Pharmaceuticals Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Other Long Term Assets

Get a 7-Day Free Trial

1.04

0.87

0.62

0.21

Syndax Pharmaceuticals Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Other Long Term Assets	Get a 7-Day Free Trial															0.62	0.43	0.35	0.20	0.21

Syndax Pharmaceuticals Other Long Term Assets Calculation

GuruFocus lists Investments And Advances, Intangible Assets, Property, Plant and Equipment and Other Long Term Assets under the "Total Long-Term Assets" section.

Other Long Term Assets includes following items:
Investment in Properties
Non-current Accounts Receivable
Non-current Note Receivables
Non-current Deferred Assets
Non-current Prepaid Assets
Defined Pension Benefit
Other (too numerous to list)
Some companies can do choose to report each of these items separately. Yet, there are a variety of Other Long Term Assets which are simply too numerous to list.

Syndax Pharmaceuticals Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Syndax Pharmaceuticals Inc (STU:1T3) » Definitions » Other Long Term Assets

Comparable Companies

Traded in Other Exchanges

SNDX:USA

Address

730 Third Avenue, 9th Floor, New York, NY, USA, 10017

Website

https://www.syndax.com

Syndax Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. Its product candidates include revumenib and axatilimab. It is developing revumenib, a selective menin-MLL inhibitor for KMT2A-rearranged (MLL-r) and NPM1-mutant acute leukemias, including ALL and AML. It is also developing axatilimab, a CSF-1R-blocking antibody for cGVHD and idiopathic pulmonary fibrosis. Entinostat is its oral, small molecule product candidate that has direct effects on both cancer cells and immune regulatory cells. The business activity of the group is functioned through the region of the United States.

Syndax Pharmaceuticals Headlines

No Headlines